Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Bad financial results growth rate -18.9% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-3.4%)
  • Dividend yield for the last twelve months 3.1%
  • Free cash flow yield 4.4% (LTM)
  • Share price is 11.0% higher than minimum and 15.2% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (22.4x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (-4.9%)157.75
year average price 154.73  


year start price 157.73 2024-04-02

min close price 142.06 2025-01-10

max close price 167.70 2025-03-10

current price 157.75 2025-04-01
Common stocks: 2 631 399 832

Dividend Yield:  3.1%
FCF Yield LTM: 4.4%
EV / LTM EBITDA: 22.4x
EV / EBITDA annualized: 18.3x
Last revenue growth (y/y):  -32.5%
Last growth of EBITDA (y/y):  -5.3%
Historical revenue growth:  +1.5%
Historical growth of EBITDA:  -8.2%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 415 103
Net Debt ($m): 6 410
EV (Enterprise Value): 421 513
EBITDA LTM ($m): 18 795
EV / LTM EBITDA: 22.4x
Price to Book: 6.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-04-01nypost.com

Judge rejects Johnson & Johnson's $10B settlement to end baby powder lawsuits

2025-04-01barrons.com

Johnson & Johnson Latest Talc Resolution Rejected. The Stock Is Falling.

2025-04-01reuters.com

J&J shares fall after judge rejects $10 billion talc settlement

2025-03-31businesswire.com

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

2025-03-31reuters.com

US judge rejects J&J's $10 billion baby powder settlement

2025-03-31zacks.com

JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

2025-03-30seekingalpha.com

Procter & Gamble, Johnson & Johnson Among 10 Companies To Announce Dividend Increases In First Half Of April

2025-03-28seekingalpha.com

Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)

2025-03-27fool.com

2 Recession-Proof Dividend Stocks to Buy and Hold

2025-03-26prnewswire.com

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data